H2020-JTI-IMI2-2017-13-two-stage
H2020-JTI-IMI2-2017-13-two-stage
- Programme
- H2020
- Funded projects (dataset)
- 13
- EU contribution (sum)
- €114,152,102
- Portal deadline
- —
Leading topic in historical projects: IMI2-2017-13-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- CAU1 coordinated
- EORTC1 coordinated
- Fraunhofer1 coordinated
- INSERM1 coordinated
- KING'S COLLEGE LONDON1 coordinated
- ROYAL COLLEGE OF SURGEONS IN IRELAND1 coordinated
- STICHTING AMSTERDAM UMC1 coordinated
- SYNAPSE1 coordinated
- UMC UTRECHT1 coordinated
- UNIVIE1 coordinated
- UZH1 coordinated
- UANTWERPEN1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- UNIVERSITAIR MEDISCH CENTRUM GRONINGEN2 topic projects
- LIH2 topic projects
- UEDIN2 topic projects
- UNIVDUN2 topic projects
- ABBOTT RAPID DX INTERNATIONAL LIMITED1 topic projects
- Leiden University Medical Center1 topic projects
- Accelerate Diagnostics S.L.1 topic projects
- AIT1 topic projects
- ALMIRALL SA1 topic projects
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- 5 shared
- 5 shared
- SARD · ELI LILLY AND COMPANY LTD5 shared
FR ↔ UK
- BAYER AKTIENGESELLSCHAFT · KU Leuven4 shared
DE ↔ BE
- 4 shared
- TAKEDA DEVELOPMENT CENTRE EUROPE LTD · TPIZ4 shared
UK ↔ CH
- ELI LILLY AND COMPANY LTD · KU Leuven4 shared
UK ↔ BE
- 4 shared
- 4 shared
- 4 shared
- JANSSEN PHARMACEUTICA NV · SARD4 shared
BE ↔ FR
- 3 shared
- 3 shared
- 3 shared
- JANSSEN PHARMACEUTICA NV · PFIZER3 shared
BE ↔ UK
- 3 shared
- 3 shared
- SARD · BAYER AKTIENGESELLSCHAFT3 shared
FR ↔ DE
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 26.46
- Median orgs / project
- 27
- Min / max orgs
- 6 – 67
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- United Kingdom64
- Germany41
- France38
- Belgium29
- Netherlands29
- Switzerland27
- Spain19
- Italy13
- United States12
- Denmark10
- Sweden10
- Austria9
- Israel8
- Luxembourg7
- Ireland7
- Norway4
- Finland4
- Czechia2
Organization types
- university87 orgs · 114 rows
- company46 orgs · 98 rows
- research_institute53 orgs · 63 rows
- sme28 orgs · 30 rows
- other18 orgs · 20 rows
- public_body14 orgs · 19 rows
Topics in funded projects
- IMI2-2017-13-01IMI2-2017-13-01· 1 projects
- IMI2-2017-13-02IMI2-2017-13-02· 1 projects
- IMI2-2017-13-03IMI2-2017-13-03· 1 projects
- IMI2-2017-13-04IMI2-2017-13-04· 1 projects
- IMI2-2017-13-05IMI2-2017-13-05· 1 projects
- IMI2-2017-13-06IMI2-2017-13-06· 1 projects
- IMI2-2017-13-07IMI2-2017-13-07· 1 projects
- IMI2-2017-13-08IMI2-2017-13-08· 1 projects
- IMI2-2017-13-09IMI2-2017-13-09· 1 projects
- IMI2-2017-13-10IMI2-2017-13-10· 1 projects
- IMI2-2017-13-11IMI2-2017-13-11· 1 projects
- IMI2-2017-13-14IMI2-2017-13-14· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| MOBILISE-D Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement | H2020 | €25,395,897 |
| IMMUcan Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts | H2020 | €17,830,000 |
| ConcePTION Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation | H2020 | €15,299,991 |
| TransBioLine Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease | H2020 | €13,999,998 |
| BIOMAP Biomarkers in Atopic Dermatitis and Psoriasis | H2020 | €10,500,000 |
| VALUE-Dx The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use | H2020 | €6,799,100 |
| CARDIATEAM CARdiomyopathy in type 2 DIAbetes mellitus | H2020 | €6,700,000 |
| NeuroDeRisk Neurotoxicity De-Risking in Preclinical Drug Discovery | H2020 | €5,331,000 |
| EBiSC2 EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells | H2020 | €4,599,648 |
| PD-MitoQUANT PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease | H2020 | €4,497,935 |
| NEURONET Efficiently Networking European Neurodegeneration Research | H2020 | €1,199,125 |
| STOPFOP Saracatinib Trial tO Prevent FOP | H2020 | €999,710 |
| PD-MIND Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug | H2020 | €999,698 |